A61K47/6435

Boronated Multifunctional Targeting Drug Conjugates, Their Uses and Methods for Their Preparation
20240150379 · 2024-05-09 ·

Tri-component multi-functional boronated complexes (B-complexes), featuring reversible covalent bonds, are described, which incorporate a drug; a water-soluble moiety (e.g. polyethylene glycol (PEG) chains, cyclodextrins); and a targeting unit. A B-complex core was assembled in one step, and proved to be stable in different biocompatible conditions, such as human plasma, though reversible for example in the presence of glutathione (GSH). This platform enabled the modular construction of the multifunctional conjugates exhibiting high selectivity towards, for example, folate-receptor-positive MDA-MB-231 cancer cells, having an IC.sub.50 in the low nanomolar range.

Engineered fluorinated biomaterials

Provided are protein polymers providing the dual functionality of delivery and imaging. The protein polymers comprise a coiled-coil domain of the cartilage oligomeric matrix protein and repeats of elastic like peptides. The coiled-coil domain allows delivery of molecules, the elastin-like peptide domain provides thermo-responsive functionality, and a plurality of leucine residues, which can be fluorinated, provide imaging functionality.

ANTIMICROBIAL BIOPOLYMER COMPOSITIONS, METHODS OF SYNTHESIS, AND APPLICATIONS OF USE
20190224362 · 2019-07-25 ·

Biopolymer compositions comprising antimicrobial peptides (AMPs) for treating infections such as bacterial infections, viral infections, fungal infections, and parasitic infections. The compositions herein may also be used for treating infections associated with antibiotic-resistant bacteria, antifungal-resistant fungi, antiviral-resistant viruses, or for treating biological warfare agents (BWAs) such as Bacillus anthracis and Yersenia pestis. The present invention also provides methods of synthesis of said biopolymer compositions, wherein AMP biopolymers can be synthesized as an artificially engineered protein by genetically fusing an AMP; a protein that behaves similarly to polymer tethers; and a protein as a modifiable material platform that can transform to self-assembled nanoparticles, self-standing films, or adhesives to easily attach tethered AMPs onto any biomaterial surface for various clinical applications.

Conductive biomaterial for enhancement of conduction in vitro and in vivo
10350237 · 2019-07-16 · ·

A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.

SALIVARY TISSUE REGENERATION USING LAMININ PEPTIDE-MODIFIED HYDROGELS
20190192739 · 2019-06-27 ·

The invention is directed to a composition comprising a fibrin hydrogel conjugated to peptides of laminin-111 (L1) and methods for repairing damaged salivary tissue using the composition.

Kidney-targeted drug delivery systems

A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and. a therapeutic agent is provided. A method of delivering a therapeutic agent to a subject in need thereof comprising: administering to the subject an effective amount of a composition comprising: an elastin-like polypeptide (ELP), a kidney targeting agent coupled to the ELP and a targeting agent and/or a drug binding domain coupled to the ELP, wherein the ELP includes an amino acid sequence having at least about repeats of the amino acid sequence GVPGX (SEQ ID NO: 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.

A PHARMACEUTICALLY ACCEPTABLE AQUEOUS GEL COMPOSITION FOR MRNA DELIVERY
20240197912 · 2024-06-20 ·

A pharmaceutically acceptable aqueous gel composition comprising a gelling agent, magnesium and/or manganese, or bivalent ions thereof, and an mRNA molecule encoding a protein of interest; and methods for inducing or facilitating repair, re-generation or generation of tissue in a human or animal subject, comprising administering the composition to the site of the tissue to be repaired, re-generated or generated.

Salvianolic acid-gelatin conjugate hydrogel particles

The present disclosure relates to salvianolic acid-gelatin conjugate load retentive hydrogel nanoparticles useful for oral delivery of salvianolic acid, pharmaceutical compositions comprising the same, and methods of use and preparation thereof.

High molecular weight biodegradable gelatin-doxorubicin conjugate

Disclosed herein are high molecular weight compounds comprising gelatin and doxorubicin, where the gelatin is covalently linked to doxorubicin through a cleavable linker. The cleavable linker can be cleaved under appropriate physiological conditions, and thus lead to the freeing of doxorubicin. The free doxorubicin can then exert its cytotoxic effects on cancer cells. Disclosed herein are methods of making the high molecular weight gelatin-doxorubicin conjugates and methods of use of the same.

Methods and compositions for delivering active agents with enhanced pharmacological properties
10258700 · 2019-04-16 · ·

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.